Illumina, Inc. (ILMN)

NasdaqGS Currently up 5.99 (+3.14%) in today's trading session

6 members of Congress have disclosed 23 trades in Illumina, Inc. (ILMN) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 10 February 2026. The most active traders have been Josh Gottheimer (9), Kathy Manning (5), and Lisa McClain (4). Aggregate disclosed activity totals roughly $96K in purchases and $112.5K in sales (midpoint estimates from bracketed disclosure amounts).

Illumina, Inc. is currently trading at $196.86, positioned at 98% of its 52-week range ($88.00 – $199.14).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$196.86
24h Change
+5.99 (+3.14%)
52 Week Range
$88.00$199.14
View on NASDAQ

Illumina, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ILMN

Select to highlight on chart
11 transactions
Compliance: 48%
Gilbert Cisneros10 Feb 20269 Mar 2026PurchaseStock$1,001 - $15,000+67.90%
Lisa McClain31 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Lisa McClain30 Oct 202521 Nov 2025PurchaseStock$1,001 - $15,000+107.16%
Lisa McClain30 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Thomas H. Kean Jr1 Apr 202515 May 2025PurchaseStock$1,001 - $15,000N/A
Thomas H. Kean Jr1 Apr 202518 Apr 2025PurchaseStock$1,001 - $15,000N/A
Thomas H. Kean Jr.19 Apr 202430 May 2024PurchaseStock$1,001 - $15,000N/A
Kathy Manning10 Jun 20227 Jul 2022SaleStock$15,001 - $50,000N/A
Josh Gottheimer6 Nov 20209 Dec 2020SaleStock$1,001 - $15,000N/A
Josh Gottheimer11 Sept 201911 Oct 2019SaleStock$1,001 - $15,000N/A
Josh Gottheimer24 Oct 201816 Nov 2018PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$29.78B

Volume

1.22M

Beta

1.47

P/E Ratio

39.14

Fundamentals

EPS

$5.03

Div. Yield

Open

$193.25

Day Range

$192.82 — $199.14

Company Information

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ · USD
Country
US
CEO
Jacob Thaysen
IPO Date
2000-07-28

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research...

Earnings

Next Report

Q2 2026

30 Jul

EPS Est.

$1.23

Rev. Est.

$1.1B

Days Until

7

Recent Quarters

Q1 202630 Apr
EPS$1.15
Beat 9.5%
Q4 20255 Feb
EPS$1.35
Beat 8.9%
Q3 202530 Oct
EPS$1.34
Beat 14.5%
Q2 202531 Jul
EPS$1.19
Beat 16.7%
Q1 20258 May
EPS$0.97
Beat 3.2%
Q4 20246 Feb
EPS$0.86
Miss 6.5%
Q3 20244 Nov
EPS$1.14
Beat 29.7%
Q2 20246 Aug
EPS$0.36
Beat 228.5%
Q1 20242 May
EPS$0.09
Beat 106.4%
Q4 20238 Feb
EPS$0.14
Beat 686.1%
Q3 20239 Nov
EPS$0.33
Beat 153.8%
Q2 20239 Aug
EPS$0.32
Beat 1636.3%
Q1 202325 Apr
EPS$0.08
Beat 215.8%
Q4 20227 Feb
EPS$0.14
Miss 26.3%
Q3 20223 Nov
EPS$0.34
Beat 17.2%
Q2 202211 Aug
EPS$0.57
Miss 9.5%
Q1 20225 May
EPS$1.07
Beat 23.0%
Q4 202110 Feb
EPS$0.75
Beat 53.1%
Q3 20214 Nov
EPS$1.45
Beat 16.9%
Q2 20215 Aug
EPS$1.87
Beat 37.5%
Q1 202127 Apr
EPS$1.89
Beat 39.0%
Q4 202011 Feb
EPS$1.22
Beat 0.8%
Q3 202029 Oct
EPS$1.02
Beat 32.5%
Q2 20206 Aug
EPS$0.62
Miss 13.9%
Q1 202030 Apr
EPS$1.64
Beat 30.2%
Q4 201929 Jan
EPS$1.70
Beat 7.6%
Q3 201924 Oct
EPS$1.93
Beat 37.9%
Q2 201929 Jul
EPS$1.35
Beat 2.3%
Q1 201925 Apr
EPS$1.60
Beat 19.4%
Q4 201829 Jan
EPS$1.32
Miss 2.9%
Q3 201823 Oct
EPS$1.52
Beat 20.6%
Q2 201830 Jul
EPS$1.43
Beat 28.8%
Q1 201824 Apr
EPS$1.45
Beat 42.2%
Q4 201730 Jan
EPS$1.44
Beat 18.0%
Q3 201724 Oct
EPS$1.11
Beat 12.1%
Q2 20171 Aug
EPS$0.82
Beat 18.8%
Q1 201725 Apr
EPS$0.64
Beat 0.0%
Q4 201631 Jan
EPS$0.85
Beat 3.7%
Q3 20161 Nov
EPS$0.97
Beat 11.5%
Q2 201626 Jul
EPS$0.86
Beat 17.8%
Q1 20163 May
EPS$0.71
Miss 4.0%
Q4 20152 Feb
EPS$0.81
Miss 1.2%
Q3 201520 Oct
EPS$0.80
Beat 1.3%
Q2 201521 Jul
EPS$0.80
Beat 3.9%
Q1 201521 Apr
EPS$0.91
Beat 26.4%
Q4 201427 Jan
EPS$0.87
Beat 11.5%
Q3 201420 Oct
EPS$0.77
Beat 37.5%
Q2 201423 Jul
EPS$0.57
Beat 11.8%
Q1 201422 Apr
EPS$0.53
Beat 20.4%
Q4 201328 Jan
EPS$0.45
Beat 2.3%
Q3 201321 Oct
EPS$0.45
Beat 12.5%
Q2 201323 Jul
EPS$0.43
Beat 10.3%
Q1 201322 Apr
EPS$0.46
Beat 21.1%
Q4 201228 Jan
EPS$0.42
Beat 2.4%
Q3 201223 Oct
EPS$0.41
Beat 5.1%
Q2 201224 Jul
EPS$0.40
Beat 8.1%
Q1 201223 Apr
EPS$0.36
Beat 9.1%
Q4 20117 Feb
EPS$0.35
Beat 12.9%
Q3 201125 Oct
EPS$0.22
Miss 4.3%
Q2 201126 Jul
EPS$0.38
Beat 2.7%
Q1 201126 Apr
EPS$0.35
Beat 12.9%
Q4 20108 Feb
EPS$0.29
Beat 0.0%
Q3 201026 Oct
EPS$0.30
Beat 25.0%
Q2 201027 Jul
EPS$0.26
Beat 13.0%
Q1 201028 Apr
EPS$0.21
Beat 10.5%
Q4 20094 Feb
EPS$0.21
Beat 5.0%
Q3 200927 Oct
EPS$0.17
Miss 15.0%
Q2 200921 Jul
EPS$0.22
Beat 22.2%
Q1 200921 Apr
EPS$0.20
Beat 5.3%
Q4 20083 Feb
EPS$0.25
Beat 47.1%
Q3 200821 Oct
EPS$0.15
Miss 6.3%
Q2 200822 Jul
EPS$0.16
Beat 14.3%
Q1 200822 Apr
EPS$0.13
Beat 8.3%
Q4 20074 Feb
EPS$0.14
Beat 16.7%
Q3 200723 Oct
EPS$0.13
Beat 30.0%
Q2 200724 Jul
EPS$0.09
Beat 50.0%
Q1 200724 Apr
EPS$0.06
Beat 42.6%
Q4 20061 Feb
EPS$0.17
Beat 13.3%
Q3 200617 Oct
EPS$0.16
Beat 100.0%
Q2 200618 Jul
EPS$0.07
Beat 409.1%
Q1 200618 Apr
EPS$-0.00
Miss 98.4%
Q4 20051 Feb
EPS$0.00
Q3 200524 Oct
EPS$-0.02
Miss 29.4%
Q2 200526 Jul
EPS$-0.04
Miss 20.7%
Q1 200527 Apr
EPS$-0.02
Miss 53.8%
Q4 200422 Feb
EPS$0.08
Beat 100.0%
Q3 200419 Oct
EPS$-0.02
Miss 28.5%
Q2 200414 Jul
EPS$-0.05
Beat 16.7%
Q1 200420 Apr
EPS$-0.06
Beat 25.0%
Q4 200327 Jan
EPS$-0.06
Beat 33.3%
Q3 200316 Oct
EPS$-0.08
Beat 27.3%
Q2 200317 Jul
EPS$-0.13
Beat 0.0%
Q1 200323 Apr
EPS$-0.14
Miss 16.7%
Q4 200228 Jan
EPS$-0.12
Beat 7.7%
Q3 200223 Oct
EPS$-0.12
Beat 14.3%
Q2 200218 Jul
EPS$-0.14
Beat 6.7%
Q1 200218 Apr
EPS$-0.14
Beat 0.0%
Q4 200131 Jan
EPS$-0.13
Miss 8.3%
Q3 20018 Nov
EPS$-0.09
Beat 10.0%
Q2 20017 Aug
EPS$-0.10
Beat 0.0%
Q1 200125 Apr
EPS$-0.08
Beat 11.1%
Q4 200030 Jan
EPS$-0.08
Beat 0.0%
Q3 20008 Nov
EPS$-0.07
Q3 200012 Oct
EPS$-0.09
Beat 10.0%
Q4 199931 Mar
EPS$-1.11

7 politicians traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

23 Sept 2008Stock Split
Ratio2:1

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

61
$1185.87+22.86 (+1.97%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

JPM

JPMorgan Chase & Co.

46
$349.90+1.69 (+0.49%)
Financial Services
3 politicians hold this stock
3 politicians
View Stock

AMZN

Amazon.com, Inc.

46
$233.66-11.19 (-4.57%)
Consumer Cyclical
3 politicians hold this stock
3 politicians
View Stock

Frequently Asked Questions about ILMN

Which members of Congress have traded ILMN?
6 members of Congress have disclosed 23 trades in Illumina, Inc. (ILMN) under the STOCK Act. The most active traders are Josh Gottheimer, Kathy Manning, and Lisa McClain.
When was ILMN most recently disclosed by Congress?
The most recent ILMN disclosure was a purchase by Gilbert Cisneros on 10 February 2026.
What is the total disclosed congressional trading volume for ILMN?
Members of Congress have disclosed approximately $96K in ILMN purchases and $112.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ILMN?
This ILMN page updates as soon as new STOCK Act disclosures are filed for Illumina, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.